FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.658,74 -630,98 (-1,05%)
Hofseth BioCare ASA (0Q6H.L)
| Chiusura precedente | 3,0100 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 35.386 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3780 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireHofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT
The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying growth is coming from both the ingredients business and finished products channels. In June, HBC announced the sale of patents to the newly established associated company, HBC Immunology Llc. (HBCI) in USA. The net proceeds from this sale of assets amounts to NOK 23.5m, resulting in total operating
- GlobeNewswire
Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000 from external investors at a company valuation of USD 20 million to commence preclinical animal trials with their patented peptides, FT-002 and FT-005. These are analogs of peptides discovered by HBC in ProGo® Bioactive Peptides which modulate iron metabolism and have Qualified Health claims granted
- GlobeNewswire
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer models” (Journal of Clinical Oncology 41, 2023, supplement 16; abstract # e15186) ahead of the annual ASCO meeting in Chicago, June 2-5, 2023. ASCO is the largest oncology organisation worldwide and the annual meeting attracts over 40,000 attendees, mainly healthcare professionals, researchers and res
